Related by context. All words. (Click for frequent words.) 69 eltrombopag 68 phase IIa clinical 67 Dacogen injection 67 Azedra 67 tocilizumab 67 posaconazole 67 sunitinib malate 66 teriflunomide 66 Amrubicin 66 Traficet EN 66 ACTEMRA 66 bendamustine 66 cilengitide 66 VELCADE 65 PNH patients 65 tolvaptan 65 phase IIb clinical 65 vandetanib 65 Zerenex 65 refractory gout 65 Cloretazine R VNP#M 65 CA4P 65 Soliris 65 JAK inhibitor 65 teduglutide 65 decitabine 65 alvespimycin 65 BAY #-# 65 OHR/AVR# 65 azacitidine 65 romiplostim 65 Soliris TM eculizumab 65 6R BH4 64 subcutaneous formulation 64 pomalidomide 64 ofatumumab 64 angiogenesis inhibitor 64 elacytarabine 64 PXD# 64 MabCampath 64 CIMZIA ™ 64 Phase 2a trial 64 lomitapide 64 FOLOTYN 64 Ophena TM 64 VAPRISOL 64 GAMMAGARD 64 rFIXFc 64 elotuzumab 64 forodesine 64 Plicera 64 rNAPc2 64 enzastaurin 64 relapsing remitting multiple sclerosis 64 PEG SN# 64 TORISEL 64 Tavocept 64 glufosfamide 64 otelixizumab 64 Cethrin 63 PROMACTA 63 riociguat 63 C1 INH 63 CIMZIA TM 63 Fx #A 63 docetaxel chemotherapy 63 PEG INTRON 63 CYT# 63 Phase Ib clinical 63 TREANDA 63 placebo controlled Phase 63 obatoclax 63 Phenoptin 63 INCB# [001] 63 relapsed refractory multiple myeloma 63 RSD# oral 63 Bezielle 63 reslizumab 63 ADHF 63 acute ischemic stroke 63 sapacitabine 63 vinorelbine 63 AP# [003] 63 YONDELIS 63 dose cohorts 63 R#/MEM # 63 ataluren 63 EOquin TM 63 Dasatinib 63 Sym# 63 visilizumab 63 Phase 2b study 63 acute coronary syndromes ACS 63 LymphoStat B 63 ISIS # 63 perifosine 63 placebo controlled clinical 63 deferiprone 63 Phase 2a clinical 63 HuMax CD4 63 Phase IIa trial 63 Amigal 63 davunetide intranasal AL 63 Fibrillex TM 63 ZYBRESTAT 62 blinatumomab 62 metaglidasen 62 DU #b 62 HCD# [002] 62 Catena ® 62 ACZ# 62 CR# vcMMAE 62 Symadex 62 subcutaneously administered 62 PRT# 62 imetelstat 62 Phase 1b 62 vidofludimus 62 CEQ# 62 odanacatib 62 CoFactor 62 HspE7 62 proteasome inhibitor 62 Clolar ® 62 samalizumab 62 Panzem R NCD 62 Mipomersen 62 XL# XL# 62 lesinurad 62 Alzhemed TM 62 AEG# 62 CTAP# Capsules 62 relapsed multiple myeloma 62 baminercept 62 cutaneous T cell 62 PEGylated interferon beta 1a 62 superficial bladder cancer 62 chlorambucil 62 Targretin 62 phase IIa 62 Triolex 62 axitinib 62 Phase IIa clinical 62 rFVIIa 62 refractory NSCLC 62 alvimopan 62 pharmacodynamic profile 62 HQK 62 pegfilgrastim 62 VIDAZA 62 icatibant 62 ELACYT 62 interferon beta 1b 62 pharmacodynamic 62 receptor tyrosine kinase inhibitor 62 sorafenib Nexavar 62 TYKERB 62 cell lymphoma CTCL 62 TACI Ig 62 registrational 62 Neuradiab 62 dasatinib 62 ospemifene 62 mRCC 62 Serdaxin 62 velafermin 62 tezampanel 61 etanercept 61 ularitide 61 lupus nephritis 61 Torisel 61 REMICADE ® 61 veltuzumab 61 immunomodulatory therapy 61 OXi# 61 Archexin 61 Teriflunomide 61 sunitinib 61 mCRC 61 rilonacept 61 NP2 Enkephalin 61 relapsing multiple sclerosis 61 ACTEMRA TM 61 Actemra 61 ambrisentan 61 Fludara 61 lubiprostone 61 leukemia AML 61 bosentan 61 metastatic RCC 61 chemotherapy induced neutropenia 61 RoACTEMRA 61 dose escalation Phase 61 adalimumab 61 nab paclitaxel 61 ZOLINZA 61 BRIM2 61 GATTEX 61 PEG Interferon lambda 61 tanespimycin 61 NGX# 61 huC# DM4 61 amrubicin 61 cangrelor 61 Eculizumab 61 ARCALYST 61 Soliris eculizumab 61 multicenter Phase II 61 tolerability 61 diabetic neuropathic pain 61 EFAPROXYN 61 brivaracetam 61 hepatic encephalopathy 61 pseudobulbar affect PBA 61 PRECiSE 61 atacicept 61 IRX 2 61 velaglucerase alfa 61 ocrelizumab 61 Nplate 61 pertuzumab 61 CYT# potent vascular disrupting 61 aHUS 61 MGCD# [001] 61 CD3 monoclonal antibody 61 Phase Ib II 61 myelofibrosis 61 bardoxolone 61 IMA# 61 talactoferrin 61 CBLC# 61 picoplatin 61 Taxotere ® 61 romidepsin 61 Tovaxin 61 MultiStem 61 basiliximab 61 dexanabinol 61 Aryplase 61 RGB # 61 galiximab 61 DAPT 61 ganetespib 61 XL# [003] 61 opioid induced bowel dysfunction 61 AA amyloidosis 61 tafamidis 61 ONTAK 61 XmAb# 61 anti leukemic 61 Tarceva TM 61 oral rivaroxaban 61 FOSRENOL ® 61 randomized discontinuation trial 61 mycophenolate mofetil 61 metastatic CRC 61 ATACAND 61 CANCIDAS 61 cancer neuroendocrine tumor 61 pralatrexate 61 pegloticase 61 lymphoma CTCL 61 ZYBRESTAT fosbretabulin 61 Pralatrexate 61 MGd 61 Cimzia ® certolizumab pegol 61 PLX cells 61 DOXIL 61 secondary hyperparathyroidism 61 UPLYSO 61 tolerability profile 61 monotherapy 61 KNS # 61 RhuDex ® 61 Apoptone 61 canakinumab 61 Myocet 61 Imprime PGG 61 APOPTONE 61 ruboxistaurin 61 oral prodrug 61 methylnaltrexone 61 tasocitinib 60 INTEGRILIN 60 rALLy clinical trial 60 hypercalcemia 60 Diabetic Macular Edema 60 hematologic malignancies 60 rALLy 60 Amplimexon 60 nitazoxanide 60 pulmonary arterial hypertension PAH 60 ISTODAX 60 Valsartan 60 pharmacokinetic PK 60 Vidofludimus 60 pexelizumab 60 vorinostat 60 prucalopride 60 GRN#L 60 interferon gamma 1b 60 ATL# [001] 60 lapatinib Tykerb 60 non metastatic osteosarcoma 60 Phase Ib 60 TEMODAL 60 MBP# [001] 60 VPRIV 60 Phase 2b trial 60 HuLuc# 60 acyclovir Lauriad R 60 XL# XL# XL# 60 dirucotide 60 LEUKINE 60 GSK# [001] 60 SUTENT ® 60 HGS# 60 paroxysmal nocturnal hemoglobinuria PNH 60 Navelbine ® 60 PD LID 60 erythropoietic 60 Augment Injectable 60 idiopathic pulmonary fibrosis IPF 60 acute HAE attacks 60 mixed dyslipidemia 60 ponatinib 60 ELND# 60 palonosetron 60 FOLOTYN ® 60 RAPAFLO 60 SILENOR TM 60 HoFH 60 Carfilzomib 60 multicenter Phase III 60 Pivotal Phase III 60 deforolimus 60 urate lowering 60 ON #.Na 60 pain palliation 60 Vidaza azacitidine 60 Phase Ib study 60 Romiplostim 60 PEGINTRON TM 60 Vascugel 60 Clonicel 60 Increlex ® 60 microplasmin 60 LY# [003] 60 CYCLOSET 60 temsirolimus 60 retinal vein occlusion 60 registrational trial 60 Taxotere R 60 irbesartan 60 Vicinium TM 60 sipuleucel T 60 G CSF 60 Androxal TM 60 mertansine 60 multiple myeloma MM 60 anakinra 60 HuMax EGFr 60 Phase 1b trial 60 phase Ib 60 forodesine hydrochloride 60 olmesartan 60 Neulasta ® 60 Pemetrexed 60 atypical hemolytic uremic syndrome 60 Friedreich Ataxia FRDA 60 ZD# [001] 60 cutaneous T 60 Alocrest 60 Epratuzumab 60 neurogenic orthostatic hypotension 60 ximelagatran 60 carfilzomib 60 CHOP chemotherapy 60 indolent NHL 60 Ceflatonin R 60 Microplasmin 60 tapentadol ER 60 antitumor activity 60 GFT# 60 OncoVEX GM CSF 60 EDEMA3 60 HGS ETR1 60 evaluating tivozanib 60 PEG PAL 60 investigational monoclonal antibody 60 MAXY G# 60 Rebif ® 60 TAXUS TM 60 heavily pretreated 60 histone deacetylase HDAC inhibitor 60 Atiprimod 60 recurrent glioblastoma multiforme 60 LUX Lung 60 R sorafenib tablets 60 terlipressin 60 novel histone deacetylase 60 Phase III 60 TAXUS Stent 60 XGEVA 60 RG# [001] 60 Aplidin 60 mTOR inhibitor 60 HER2 positive metastatic breast 60 Myelodysplastic Syndrome MDS 60 HuMax CD# 60 Aclidinium 60 metastatic HRPC 60 dose limiting toxicities 60 phase IIb 60 docetaxel Taxotere ® 60 TMS Therapy 60 laquinimod 60 MabThera rituximab 60 oral anticoagulant 60 abiraterone acetate 60 bevacizumab Avastin 60 Doxil ® 60 TMC# [002] 60 INCB# [003] 60 Pyridorin 60 Pirfenidone 60 AZX# 60 Viprinex 60 Capesaris 60 Increlex R 60 Glypromate 60 CCX# 60 RSD# 60 RITUXAN 60 efficacy endpoint 60 pegylated liposomal doxorubicin 60 MAGE A3 ASCI 60 dirucotide MBP# 60 MyoCell 60 pan HDAC inhibitor 60 AGILECT R 60 NATRECOR ® 60 celgosivir 60 liposomal formulation 60 lixisenatide 60 EVIZON 60 OZURDEX ® 60 hypoparathyroidism 60 MYDICAR ® 60 depsipeptide 60 PEGylated Fab fragment 59 BrachySil TM 59 confirmatory Phase III 59 schizophrenia CIAS 59 FOLFIRI 59 selective androgen receptor modulator 59 Androxal 59 chronic ITP patients 59 Panzem R 59 dose escalation 59 Aflibercept 59 calcineurin inhibitor 59 clofarabine 59 systemically administered 59 B CLL 59 catheter occlusion 59 MabThera Rituxan 59 CD# antibody [001] 59 metastatic castration resistant 59 TNF alpha inhibitor 59 adult chronic ITP 59 ISA# [002] 59 Proxinium TM 59 SNT MC# 59 myeloproliferative disorders 59 MDV# 59 ORENCIA ® 59 ancrod 59 ARCOXIA 59 Cloretazine 59 MIRCERA 59 relapsed MM 59 generation purine nucleoside 59 Bicifadine 59 Phase 2a 59 TYZEKA 59 VELCADE melphalan 59 LEVADEX 59 dexpramipexole 59 eniluracil 59 biologic therapy 59 Etanercept 59 SCH # 59 PEGylated anti 59 Arcalyst 59 ALN TTR# 59 Campath ® 59 Chemophase 59 NVA# 59 refractory chronic lymphocytic 59 GEM OS2 59 dextromethorphan quinidine 59 Phase III clinical 59 cariprazine 59 edoxaban 59 fidaxomicin 59 Xyrem ® 59 invasive candidiasis 59 severe hypercholesterolemia 59 cannabinor 59 cetuximab Erbitux ® 59 MNTX 59 Noxafil 59 Elotuzumab 59 tgAAC# 59 administered subcutaneously 59 PI3K/Akt pathway inhibitor 59 TRO# 59 NUVIGIL 59 gastrointestinal stromal tumor GIST 59 bicifadine 59 febuxostat 59 docetaxel Taxotere R 59 anticancer compound 59 dosing cohort 59 thalidomide Thalomid 59 eculizumab therapy 59 diabetic gastroparesis 59 tesetaxel 59 SUTENT 59 Genz # 59 urocortin 2 59 Tyrima 59 TRISENOX 59 CINQUIL 59 TRIOLEX 59 zileuton 59 PSN# [002] 59 BENLYSTA ® 59 sitaxsentan 59 DP b# 59 dasatinib Sprycel ® 59 Gabapentin GR 59 rFVIIIFc 59 xanthine oxidase inhibitor 59 MYDICAR 59 atypical Hemolytic Uremic Syndrome 59 Firazyr 59 oral ridaforolimus 59 PRTX 59 randomized Phase III 59 erlotinib Tarceva ® 59 aflibercept 59 Northera 59 Keppra ® 59 clevidipine 59 mGluR5 NAM 59 ToGA 59 lintuzumab SGN 59 omecamtiv mecarbil 59 dose escalation clinical 59 SPRYCEL ® 59 refractory CTCL 59 JANUVIA 59 diabetic nephropathy 59 active comparator 59 EndoTAG TM -1 59 TELINTRA 59 briakinumab 59 Onco TCS 59 AGGRASTAT ® 59 FOLFOX4 59 PREOS 59 vemurafenib 59 panitumumab 59 Phase IIa trials 59 TELCYTA 59 epratuzumab 59 cediranib 59 adecatumumab 59 AVONEX ® 59 familial amyloidotic polyneuropathy FAP 59 Raptiva ® 59 eosinophilic asthma 59 Ilaris 59 valopicitabine 59 acute promyelocytic leukemia APL 59 fosbretabulin 59 analgesic efficacy 59 coadministration 59 MACUGEN 59 placebo controlled Phase III 59 GGF2 59 RAPTIVA 59 efalizumab 59 atherothrombotic events 59 TG# [003] 59 Clolar 59 Cloretazine ® 59 nilotinib 59 Azixa 59 tamibarotene 59 unique alkylating agent 59 Vaprisol 59 ENMD # 59 antiplatelet agent 59 metastatic renal cell carcinoma 59 Acute Myeloid Leukemia AML 59 anti TNF 59 dose cohort 59 ascending dose 59 TYSABRI natalizumab 59 Treanda 59 CLL SLL 59 Phase #/#a 59 angiotensin receptor blocker ARB 59 Asentar 59 severe gastroparesis 59 ecallantide 59 anti TNF alpha 59 AZILECT R 59 hemolysis 59 rHuPH# 59 Vandetanib 59 ranolazine 59 Onrigin 59 dopamine partial agonist 59 ADAGIO study 59 dose escalation trial 59 Factor VIIa 59 Entereg R 59 RLY# 59 metastatic malignant 59 gastrointestinal stromal tumors GIST 59 lenalidomide Revlimid R 59 albinterferon alfa 2b 59 Evoltra 59 refractory AML 59 Zenvia ™ 59 PROVENGE 59 octreotide implant 59 TBC# 59 FROVA 59 CTA# Injection 59 refractory multiple myeloma 59 STELARA 59 AGGRASTAT R 59 pazopanib 59 fostamatinib 59 Adalimumab 59 Phase 2b clinical 59 Xanafide 59 BioNumerik 59 PDX pralatrexate 59 NeuroStar TMS Therapy 59 Vidaza 59 plasma kallikrein inhibitor 59 SEROQUEL 59 dabigatran etexilate 59 bevacizumab Avastin ® 59 Cleviprex TM clevidipine 59 humanized anti 59 Benlysta belimumab 59 VA# [002] 59 crizotinib PF # 59 Enzyme Replacement Therapy 59 ADVANCE PD 59 apremilast 59 INT# [002] 59 Ceflatonin 59 refractory Hodgkin lymphoma 59 venous thromboembolic events 59 BRIM3 59 Ixempra 59 Chrysalin 59 Cimzia TM 59 blinded randomized placebo controlled 59 refractory acute myeloid 59 Phase III placebo controlled 59 oxypurinol 59 Pimavanserin 59 ZACTIMA 59 proteasome inhibitor bortezomib 59 pharmacodynamic PD 59 novel VDA molecule 59 thymalfasin 59 Tocilizumab 59 acute decompensated heart 59 Nuvion 59 Lubiprostone 58 Virulizin ® 58 SRT# [003] 58 lucinactant 58 plus dexamethasone 58 ORENCIA R 58 Phase IIIb clinical 58 Actemra tocilizumab 58 dosing regimens 58 ATL/TV# 58 motesanib 58 diarrhea predominant irritable 58 NEVO ™ 58 Plenaxis TM 58 DDP# 58 entinostat 58 PRADAXA 58 peritumoral brain edema 58 ® natalizumab 58 SEPET TM 58 pharmacokinetics PK 58 #mg dose [001] 58 tipranavir 58 Evoltra ® 58 ongoing Phase 1b 58 IPLEX 58 Alemtuzumab 58 Keppra R 58 Enzastaurin 58 Pegasys ® 58 GW# [003] 58 PegIntron 58 RECOTHROM 58 MAP# 58 idraparinux 58 melphalan prednisone 58 Cutaneous T 58 MEK inhibitors 58 afatinib 58 APTIVUS 58 recurrent GBM 58 Azedra TM 58 peginesatide 58 cardiac toxicity 58 ganaxolone 58 Gleevec imatinib 58 BEXXAR 58 sorafenib tablets 58 KIACTA ™ 58 Phase IIa 58 Phase 1b clinical 58 chemoradiotherapy 58 aflibercept VEGF Trap 58 GEM OS1 58 Trastuzumab 58 anticancer therapies 58 Behcet uveitis 58 valsartan 58 histamine dihydrochloride 58 primary hypercholesterolemia 58 selective modulator 58 sodium thiosulfate STS 58 bevacizumab 58 huN# DM1 58 ozarelix 58 phase III ACCLAIM 58 TNF antagonist 58 PROCHYMAL 58 mTOR inhibitors 58 Locteron 58 bortezomib Velcade 58 homozygous familial hypercholesterolemia 58 Gemzar ® 58 KRN# 58 Bortezomib 58 Specifid 58 rituximab Rituxan 58 angiographic outcomes 58 GOUT 58 imatinib therapy 58 Forodesine HCl 58 Troxatyl 58 Icatibant 58 AVASTIN 58 NTx TM -# 58 Cimzia ® 58 REMINYL ® 58 neratinib 58 Nasulin 58 docetaxel Taxotere 58 PRX# 58 TREDAPTIVE 58 GLYX 58 double blinded placebo 58 tumor lysis syndrome 58 sJIA 58 omacetaxine 58 bardoxolone methyl 58 multicentre randomized 58 Fibrin Pad 58 pemetrexed 58 bazedoxifene 58 weekly subcutaneous injections 58 orally administered inhibitor 58 mipomersen 58 Lixivaptan 58 belinostat 58 rufinamide 58 LAF# 58 Pertuzumab 58 GetGoal Phase III 58 BENLYSTA TM 58 oral FTY# 58 Hepatocellular Carcinoma HCC 58 INCB# [002] 58 eluting stent 58 Cloretazine R 58 safety tolerability pharmacokinetic 58 linaclotide 58 pharmacodynamics PD 58 ezogabine 58 Cotara 58 Golimumab 58 colorectal liver metastases 58 sorafenib Nexavar ® 58 dose regimens 58 symptomatic neurogenic orthostatic hypotension 58 pitavastatin 58 PLX PAD 58 Mylotarg 58 Revlimid lenalidomide 58 intravesical 58 Phase 2b 58 investigational humanized monoclonal antibody 58 eprotirome 58 Phase IIb trials 58 JAK inhibitors 58 TYGACIL 58 targeted radiotherapeutic 58 Octreolin 58 Dapagliflozin 58 APTIVUS r 58 goserelin 58 ARCALYST ® 58 radiation sensitizer 58 octreotide 58 #ME# 58 paclitaxel Taxol 58 senicapoc 58 efficacy endpoints 58 FOLPI 58 Ozarelix 58 systemic lupus erythematosus SLE 58 AeroLEF TM 58 candesartan cilexetil 58 figitumumab 58 IMiDs 58 elesclomol 58 NEUVENGE 58 non splenectomized 58 Azilect ® 58 refractory cutaneous T 58 lanthanum carbonate 58 Natalizumab 58 Defibrotide 58 nonrandomized 58 CLARITY study 58 multi kinase inhibitor 58 Lenalidomide 58 drug ISA# 58 LHRH agonists 58 alkylating agent 58 aclidinium 58 PREOS R 58 FavId 58 gefitinib 58 voreloxin 58 pivotal Phase III 58 Eltrombopag 58 phase IIb trial 58 BRAF inhibitor 58 Phase IIb trial 58 IBS C 58 peptibody 58 IGIV 58 sorafenib 58 TOLAMBA 58 FTY# 58 advanced carcinoid 58 cetrorelix 58 GRNCM1 58 Laquinimod 58 Ophena 58 HGS ETR2 58 delayed CINV 58 subcutaneous SC 58 idiopathic thrombocytopenic purpura ITP 58 Simulect 58 TPI ASM8 58 Reolysin 58 Zemplar Capsules 58 TNF Tumor Necrosis Factor 58 SUPPRELIN R LA 58 Zavesca ® 58 ALN TTR 58 TKM ApoB 58 Alpharadin 58 Neulasta R 58 Nexavar ® 58 rotigotine transdermal patch 58 TG# [001] 58 trial evaluating PRX# 58 CCR9 antagonist 58 neoadjuvant 58 alefacept 58 oxymorphone ER 58 myeloproliferative diseases 58 CIMZIA TM certolizumab pegol 58 PAOD 58 darapladib 58 chronic lymphocytic leukemia CLL 58 cinacalcet HCl 58 favorable pharmacokinetic profile 58 HMG CoA reductase inhibitors 58 Rituxan rituximab 58 synthetic retinoid 58 varespladib 58 DR Cysteamine 58 Methylnaltrexone 58 S/GSK# 58 novel oral anticoagulant 58 either acutely decompensated 58 Nanobody 58 oral antiviral 58 SinuNase TM 58 IRESSA 58 Ambrisentan 58 Leukine 58 brentuximab vedotin 58 ULORIC 58 gefitinib Iressa 58 Seliciclib 58 randomized clinical 58 anti fibrotic 58 HCV protease inhibitor 58 secondary efficacy endpoints 58 vicriviroc 58 dyskinesia PD LID 58 ERBITUX 58 PKC# 58 humanized monoclonal antibody 58 temozolomide 58 vernakalant 58 Omacetaxine 58 volociximab 58 LymphoStat B belimumab 58 antibody MAb 58 TTF Therapy 58 Uricase PEG 58 relapsed AML 58 plus DOXIL 58 Celacade TM technology 58 inhibitor RG# 58 noninfectious uveitis 58 Vectibix monotherapy 58 MYLOTARG 58 Tolvaptan 58 immune modulator 58 Triapine 57 cobiprostone 57 AzaSite Plus 57 mitoxantrone 57 tolerability profiles 57 Zavesca R 57 Elagolix 57 CK # 57 Annamycin 57 CYPHER R Sirolimus eluting 57 evaluating REVLIMID 57 CCX# B 57 Vfend 57 ramelteon 57 MGCD# [002] 57 Tarceva erlotinib 57 ASA# 57 torezolid phosphate 57 ® bortezomib 57 Lialda 57 Phase IIb clinical 57 Xelox 57 Phase IIB 57 PNP inhibitor 57 desvenlafaxine succinate 57 Lu AA# 57 custirsen 57 RRMS 57 alemtuzumab Campath 57 Degarelix 57 imatinib mesylate Gleevec 57 ixabepilone 57 antithrombotic 57 RDEA# 57 BCX# 57 XIENCE V stent 57 perampanel 57 phase 2a 57 post herpetic neuralgia PHN 57 forodesine HCl 57 LEXIVA r 57 Epoetin alfa